Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

FDA approvals usher in the post-interferon era in HCV

Nature Biotechnology volume 32, pages 3–5 (2014)Cite this article

Subjects

For more than two decades, interferon has been a cornerstone of HCV therapy. But it carries a heavy burden of side effects, and current regimens, based on one of two approved protease inhibitors Incivek (telaprevir) or Victrelis (boceprevir), plus ribavirin, all include pegylated interferon-α.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sheridan, C. FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol 32, 3–5 (2014). https://doi.org/10.1038/nbt0114-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0114-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing